Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Postoperative quadriceps strength of continuous femoral ropivacaine or levobupivacaine: a prospective, randomized double-blind trial after total knee arthroplasty

Next Previous
Trial Profile

Postoperative quadriceps strength of continuous femoral ropivacaine or levobupivacaine: a prospective, randomized double-blind trial after total knee arthroplasty

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levobupivacaine (Primary) ; Ropivacaine (Primary)
  • Indications Postoperative pain
  • Focus Pharmacodynamics

Most Recent Events

  • 01 Sep 2013 Status changed from suspended to discontinued as reported by University Hospital Medical Information Network - Japan.
  • 23 Feb 2013 Status changed from not yet recruiting to suspended as reported by University Hospital Medical Information Network - Japan.
  • 27 Oct 2012 Planned initiation date changed from 7 Nov 2012 to 1 Apr 2013 as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top